The Parkinson’ s Pipeline: Measuring Progress toward New Treatments
A robust therapeutic pipeline includes drugs at every phase of the clinical development process. As of August 2025, the Foundation is tracking 178 unique treatments targeting a range of Parkinson’ s biology and symptoms. Some are in early Phase I research, undergoing testing in a handful of volunteers living without PD. Others are in critical Phase III testing, with hundreds of people with Parkinson’ s receiving treatment so researchers can collect data on outcomes, ranging from how safe a drug is to how effectively it manages a specific symptom or slows progression of disease.
16